US6232320B1
(en)
|
1998-06-04 |
2001-05-15 |
Abbott Laboratories |
Cell adhesion-inhibiting antiinflammatory compounds
|
CA2320730A1
(en)
*
|
1998-12-23 |
2000-07-06 |
Renhua Li |
Thrombin or factor xa inhibitors
|
ATE226208T1
(en)
|
1999-03-09 |
2002-11-15 |
Upjohn Co |
4-OXO-4,7-DIHYDRO-THIENO(2,3-B)PYRIDINE-5-CARBOXAMIDE AS ANTIVIRAL AGENTS
|
EP1181296A1
(en)
*
|
1999-06-03 |
2002-02-27 |
Abbott Laboratories |
Cell adhesion-inhibiting antiinflammatory compounds
|
ATE301651T1
(en)
*
|
1999-06-23 |
2005-08-15 |
Aventis Pharma Gmbh |
SUBSTITUTED BENZIMIDAZOLES
|
US6689883B1
(en)
|
1999-09-28 |
2004-02-10 |
Bayer Pharmaceuticals Corporation |
Substituted pyridines and pyridazines with angiogenesis inhibiting activity
|
WO2001058878A1
(en)
*
|
2000-02-09 |
2001-08-16 |
The Procter & Gamble Company |
2-carboxamide-benzimidazoles useful in the treatment and prevention of ischemic reperfusion injury
|
US7977333B2
(en)
|
2000-04-20 |
2011-07-12 |
Bayer Healthcare Llc |
Substituted pyridines and pyridazines with angiogenesis inhibiting activity
|
PL366799A1
(en)
|
2001-07-27 |
2005-02-07 |
Curis, Inc. |
Mediators of hedgehog signaling pathways, compositions and uses related thereto
|
WO2003020728A1
(en)
|
2001-08-30 |
2003-03-13 |
Pharmacia & Upjohn Company |
4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS
|
WO2003020729A1
(en)
|
2001-08-30 |
2003-03-13 |
Pharmacia & Upjohn Company |
4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOXAMIDES AS ANT IVIRAL AGENTS
|
AR038294A1
(en)
|
2002-01-14 |
2005-01-12 |
Upjohn Co |
OXOTIENE (3,2-B) PYRIDINCARBOXAMIDS AS ANTIVIRAL AGENTS
|
AR038118A1
(en)
|
2002-01-14 |
2004-12-29 |
Upjohn Co |
COMPOUNDS DERIVED FROM ACID BENCINAMIDE 7-OXO-4,7-DIHIDROTIEN [2,3-B [PIRIDIN-6-CARBOXYLIC 3-REPLACED WHICH ARE USEFUL AS ANTIVIRAL
|
AR038117A1
(en)
|
2002-01-14 |
2004-12-29 |
Upjohn Co |
ANTIVIRAL AGENTS DERIVED FROM 4- OXO-4,7 -DIHYDROFIDE [2,3-B] PIRIDIN-5-CARBOXAMIDA
|
KR20050006237A
(en)
|
2002-05-06 |
2005-01-15 |
버텍스 파마슈티칼스 인코포레이티드 |
Thiadiazoles or oxadiazoles and their use as inhibitors of JAK protein kinase
|
AU2003246972A1
(en)
|
2002-08-06 |
2004-02-23 |
Astrazeneca Ab |
Condensed pyridines and pyrimidines with tie2 (tek) activity
|
IL154306A0
(en)
*
|
2003-02-05 |
2003-09-17 |
Rimonyx Pharmaceuticals Ltd |
Pharmaceutical compositions comprising thieno [2,3-c] pyridine derivatives and use thereof
|
JP2007536301A
(en)
*
|
2004-05-04 |
2007-12-13 |
エフ.ホフマン−ラ ロシュ アーゲー |
Thienopyridazine as an IKK inhibitor
|
JP2007536303A
(en)
*
|
2004-05-04 |
2007-12-13 |
エフ.ホフマン−ラ ロシュ アーゲー |
Thienopyridine as an IKK inhibitor
|
MXPA06013250A
(en)
*
|
2004-05-14 |
2007-02-28 |
Abbott Lab |
Kinase inhibitors as therapeutic agents.
|
US7714130B2
(en)
|
2004-06-17 |
2010-05-11 |
Wyeth |
Processes for preparing gonadotropin releasing hormone receptor antagonists
|
WO2006009734A1
(en)
|
2004-06-17 |
2006-01-26 |
Wyeth |
Gonadotropin releasing hormone receptor antagonists
|
WO2006010264A1
(en)
|
2004-07-30 |
2006-02-02 |
Methylgene, Inc. |
Inhibitors of vegf receptor and hgf receptor signaling
|
BRPI0514094A
(en)
|
2004-08-02 |
2008-05-27 |
Osi Pharm Inc |
compound, composition, and method of treating hyperproliferative disorder
|
GB0420722D0
(en)
|
2004-09-17 |
2004-10-20 |
Addex Pharmaceuticals Sa |
Novel allosteric modulators
|
KR20140008471A
(en)
*
|
2004-10-21 |
2014-01-21 |
다우 아그로사이언시즈 엘엘씨 |
Thieno-pyrimidine compounds having fungicidal activity
|
MY179032A
(en)
|
2004-10-25 |
2020-10-26 |
Cancer Research Tech Ltd |
Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
|
US7674822B2
(en)
|
2004-11-24 |
2010-03-09 |
Wyeth |
PTP1b inhibitors
|
AR054416A1
(en)
|
2004-12-22 |
2007-06-27 |
Incyte Corp |
PIRROLO [2,3-B] PIRIDIN-4-IL-AMINAS AND PIRROLO [2,3-B] PIRIMIDIN-4-IL-AMINAS AS INHIBITORS OF THE JANUS KINASES. PHARMACEUTICAL COMPOSITIONS.
|
US7538113B2
(en)
|
2005-02-18 |
2009-05-26 |
Wyeth |
4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
|
US7582634B2
(en)
|
2005-02-18 |
2009-09-01 |
Wyeth |
7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
|
US7534796B2
(en)
|
2005-02-18 |
2009-05-19 |
Wyeth |
Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
|
US7531542B2
(en)
|
2005-05-18 |
2009-05-12 |
Wyeth |
Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
|
MX2007014616A
(en)
|
2005-05-20 |
2009-08-12 |
Methylgene Inc |
Inhibitors of vegf receptor and hgf receptor signaling.
|
ES2473341T3
(en)
|
2005-05-20 |
2014-07-04 |
Methylgene Inc |
Inhibitors of VEGF receptor and HGF receptor signaling
|
US7582636B2
(en)
|
2005-05-26 |
2009-09-01 |
Wyeth |
Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
|
EP2251341A1
(en)
|
2005-07-14 |
2010-11-17 |
Astellas Pharma Inc. |
Heterocyclic Janus kinase 3 inhibitors
|
EP1910358A2
(en)
|
2005-07-14 |
2008-04-16 |
Astellas Pharma Inc. |
Heterocyclic janus kinase 3 inhibitors
|
US8921406B2
(en)
|
2005-08-21 |
2014-12-30 |
AbbVie Deutschland GmbH & Co. KG |
5-ring heteroaromatic compounds and their use as binding partners for 5-HT5 receptors
|
US20070149506A1
(en)
|
2005-09-22 |
2007-06-28 |
Arvanitis Argyrios G |
Azepine inhibitors of Janus kinases
|
TWI468162B
(en)
|
2005-12-13 |
2015-01-11 |
英塞特公司 |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
|
AR059898A1
(en)
|
2006-03-15 |
2008-05-07 |
Janssen Pharmaceutica Nv |
DERIVATIVES OF 3-CIANO-PIRIDONA 1,4-DISUSTITUTED AND ITS USE AS ALLOSTERIC MODULATORS OF MGLUR2 RECEIVERS
|
DK3421471T3
(en)
|
2006-04-25 |
2021-06-14 |
Astex Therapeutics Ltd |
PURIN AND DEAZAPURIN DERIVATIVES AS PHARMACEUTICAL COMPOUNDS
|
US8227603B2
(en)
|
2006-08-01 |
2012-07-24 |
Cytokinetics, Inc. |
Modulating skeletal muscle
|
KR101410453B1
(en)
|
2006-08-02 |
2014-06-27 |
싸이토키네틱스, 인코포레이티드 |
Certain chemical entities, compositions and methods
|
US8299248B2
(en)
|
2006-08-02 |
2012-10-30 |
Cytokinetics, Incorporated |
Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
|
US8513270B2
(en)
|
2006-12-22 |
2013-08-20 |
Incyte Corporation |
Substituted heterocycles as Janus kinase inhibitors
|
TW200845978A
(en)
|
2007-03-07 |
2008-12-01 |
Janssen Pharmaceutica Nv |
3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
|
TW200900065A
(en)
|
2007-03-07 |
2009-01-01 |
Janssen Pharmaceutica Nv |
3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
|
WO2008121333A1
(en)
|
2007-03-30 |
2008-10-09 |
Cytokinetics, Incorporated |
Certain chemical entities, compositions and methods
|
SG10201509887UA
(en)
|
2007-06-13 |
2016-01-28 |
Incyte Corp |
Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
|
CL2008001709A1
(en)
|
2007-06-13 |
2008-11-03 |
Incyte Corp |
Compounds derived from pyrrolo [2,3-b] pyrimidine, jak kinase modulators; pharmaceutical composition; and use in the treatment of diseases such as cancer, psoriasis, rheumatoid arthritis, among others.
|
KR20100065191A
(en)
|
2007-09-14 |
2010-06-15 |
오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 |
1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
|
CN101801951B
(en)
|
2007-09-14 |
2013-11-13 |
杨森制药有限公司 |
1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1, 4'] bipyridinyl-2'-ones
|
MY150059A
(en)
|
2007-10-11 |
2013-11-29 |
Astrazeneca Ab |
Pyrrolo [2,3-d] pyrimidin derivatives as protein kinase b inhibitors
|
MY152948A
(en)
|
2007-11-16 |
2014-12-15 |
Incyte Corp |
4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
|
GEP20125664B
(en)
|
2008-02-26 |
2012-10-10 |
Takeda Pharmaceuticals Co |
Condensed heterocyclic derivatives and application thereof
|
EP2262815A4
(en)
|
2008-03-05 |
2012-04-11 |
Methylgene Inc |
Inhibitors of protein tyrosine kinase activity
|
ES2602577T3
(en)
|
2008-03-11 |
2017-02-21 |
Incyte Holdings Corporation |
Azetidine and cyclobutane derivatives as JAK inhibitors
|
JP2011518836A
(en)
|
2008-04-24 |
2011-06-30 |
インサイト・コーポレイション |
Macrocycles and their use as kinase inhibitors
|
RU2510396C2
(en)
|
2008-09-02 |
2014-03-27 |
Янссен Фармасьютикалз, Инк. |
3-azabicyclo[3,1,0]hexyl derivatives as modulators of metabotropic glutamate receptors
|
AU2009319387B2
(en)
|
2008-11-28 |
2012-05-10 |
Addex Pharma S.A. |
Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
|
US8765727B2
(en)
|
2009-01-23 |
2014-07-01 |
Incyte Corporation |
Macrocyclic compounds and their use as kinase inhibitors
|
JP5707390B2
(en)
|
2009-05-12 |
2015-04-30 |
ジャンセン ファーマシューティカルズ, インコーポレイテッド |
1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of the mGluR2 receptor
|
RS53075B
(en)
|
2009-05-12 |
2014-04-30 |
Janssen Pharmaceuticals Inc. |
1,2,4-triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
|
MY153913A
(en)
|
2009-05-12 |
2015-04-15 |
Janssen Pharmaceuticals Inc |
7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
|
EA025520B1
(en)
|
2009-05-22 |
2017-01-30 |
Инсайт Холдингс Корпорейшн |
N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
|
SG176111A1
(en)
|
2009-05-22 |
2011-12-29 |
Incyte Corp |
3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
|
WO2010151317A1
(en)
|
2009-06-22 |
2010-12-29 |
Millennium Pharmaceuticals, Inc. |
Substituted hydroxamic acids and uses thereof
|
US9096518B2
(en)
|
2009-06-22 |
2015-08-04 |
Millennium Pharmaceuticals, Inc. |
Substituted hydroxamic acids and uses thereof
|
WO2011028685A1
(en)
|
2009-09-01 |
2011-03-10 |
Incyte Corporation |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
US8486902B2
(en)
|
2009-10-09 |
2013-07-16 |
Incyte Corporation |
Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
|
MX347851B
(en)
|
2010-03-10 |
2017-05-16 |
Incyte Corp |
Piperidin-4-yl azetidine derivatives as jak1 inhibitors.
|
EP2574168B9
(en)
|
2010-05-21 |
2016-10-05 |
Incyte Holdings Corporation |
Topical formulation for a jak inhibitor
|
CN102260270A
(en)
*
|
2010-05-28 |
2011-11-30 |
中国科学院上海药物研究所 |
N-(2-methylfuran[2,3-d]pyrimidine-4-yl)acrylamide, its preparation method and application
|
EP2643320B1
(en)
|
2010-11-08 |
2015-03-04 |
Janssen Pharmaceuticals, Inc. |
1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
|
EP2649069B1
(en)
|
2010-11-08 |
2015-08-26 |
Janssen Pharmaceuticals, Inc. |
1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
|
EP2661435B1
(en)
|
2010-11-08 |
2015-08-19 |
Janssen Pharmaceuticals, Inc. |
1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
|
WO2012068450A1
(en)
|
2010-11-19 |
2012-05-24 |
Incyte Corporation |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
|
US9034884B2
(en)
|
2010-11-19 |
2015-05-19 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
|
US8778931B2
(en)
|
2010-12-22 |
2014-07-15 |
Millennium Pharmaceuticals, Inc. |
Substituted hydroxamic acids and uses thereof
|
AU2012219395B2
(en)
|
2011-02-18 |
2017-05-25 |
Incyte Corporation |
mTOR/JAK inhibitor combination therapy
|
EP2694056B1
(en)
|
2011-04-01 |
2019-10-16 |
AstraZeneca AB |
Therapeutic treatment
|
CA2839767A1
(en)
|
2011-06-20 |
2012-12-27 |
Incyte Corporation |
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
|
CA2841111A1
(en)
|
2011-07-08 |
2013-01-17 |
Novartis Ag |
Novel pyrrolo pyrimidine derivatives
|
JP6145946B2
(en)
|
2011-07-13 |
2017-06-14 |
サイトキネティックス, インコーポレイテッド |
Combined ALS therapy
|
WO2013023119A1
(en)
|
2011-08-10 |
2013-02-14 |
Novartis Pharma Ag |
JAK P13K/mTOR COMBINATION THERAPY
|
TW201313721A
(en)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
Cyclohexyl azetidine derivatives as JAK inhibitors
|
UA111854C2
(en)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
|
WO2013079964A1
(en)
|
2011-11-30 |
2013-06-06 |
Astrazeneca Ab |
Combination treatment of cancer
|
PT2797416T
(en)
|
2011-12-28 |
2017-10-23 |
Global Blood Therapeutics Inc |
Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
|
ES2790358T3
(en)
|
2011-12-28 |
2020-10-27 |
Global Blood Therapeutics Inc |
Substituted Heteroaryl Aldehyde Compounds and Methods for Their Use in Increasing Tissue Oxygenation
|
AU2013204533B2
(en)
|
2012-04-17 |
2017-02-02 |
Astrazeneca Ab |
Crystalline forms
|
US9193733B2
(en)
|
2012-05-18 |
2015-11-24 |
Incyte Holdings Corporation |
Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
|
BR112015010663B1
(en)
|
2012-11-15 |
2022-12-06 |
Incyte Holdings Corporation |
SUSTAINED RELEASE ORAL DOSAGE FORMS AND USE OF RUXOLITINIB OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
|
CN105189509B
(en)
|
2013-03-06 |
2017-12-19 |
因赛特公司 |
For preparing the method and intermediate of JAK inhibitor
|
MY180206A
(en)
|
2013-03-15 |
2020-11-25 |
Global Blood Therapeutics Inc |
Compounds and uses thereof for the modulation of hemoglobin
|
US20140274961A1
(en)
|
2013-03-15 |
2014-09-18 |
Global Blood Therapeutics, Inc. |
Compounds and uses thereof for the modulation of hemoglobin
|
US9604999B2
(en)
|
2013-03-15 |
2017-03-28 |
Global Blood Therapeutics, Inc. |
Compounds and uses thereof for the modulation of hemoglobin
|
CN105073728A
(en)
|
2013-03-15 |
2015-11-18 |
全球血液疗法股份有限公司 |
Compounds and uses thereof for the modulation of hemoglobin
|
US8952171B2
(en)
|
2013-03-15 |
2015-02-10 |
Global Blood Therapeutics, Inc. |
Compounds and uses thereof for the modulation of hemoglobin
|
US9422279B2
(en)
|
2013-03-15 |
2016-08-23 |
Global Blood Therapeutics, Inc. |
Compounds and uses thereof for the modulation of hemoglobin
|
US9458139B2
(en)
|
2013-03-15 |
2016-10-04 |
Global Blood Therapeutics, Inc. |
Compounds and uses thereof for the modulation of hemoglobin
|
US10100043B2
(en)
|
2013-03-15 |
2018-10-16 |
Global Blood Therapeutics, Inc. |
Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
|
US10266551B2
(en)
|
2013-03-15 |
2019-04-23 |
Global Blood Therapeutics, Inc. |
Compounds and uses thereof for the modulation of hemoglobin
|
AP2015008718A0
(en)
|
2013-03-15 |
2015-09-30 |
Global Blood Therapeutics Inc |
Compounds and uses thereof for the modulation of hemoglobin
|
JO3368B1
(en)
|
2013-06-04 |
2019-03-13 |
Janssen Pharmaceutica Nv |
6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
|
RS60469B1
(en)
|
2013-08-07 |
2020-07-31 |
Incyte Corp |
Sustained release dosage forms for a jak1 inhibitor
|
JO3367B1
(en)
|
2013-09-06 |
2019-03-13 |
Janssen Pharmaceutica Nv |
1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
|
EA201992707A1
(en)
|
2013-11-18 |
2020-06-30 |
Глобал Блад Терапьютикс, Инк. |
COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION
|
BR112016011727A2
(en)
|
2013-11-22 |
2017-08-08 |
CL BioSciences LLC |
GASTRIN ANTAGONISTS FOR THE TREATMENT AND PREVENTION OF OSTEOPOROSIS
|
DK3431106T3
(en)
|
2014-01-21 |
2021-03-15 |
Janssen Pharmaceutica Nv |
COMBINATIONS INCLUDING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROP GLUTAMATERG SUBTYPE 2 RECEPTOR AND USE OF THESE
|
ES2860298T3
(en)
|
2014-01-21 |
2021-10-04 |
Janssen Pharmaceutica Nv |
Combinations comprising positive allosteric modulators of metabotropic glutamatergic receptor subtype 2 and their use
|
DK3102208T3
(en)
|
2014-02-07 |
2021-03-08 |
Global Blood Therapeutics Inc |
CRYSTALLINIC POLYMORPH OF THE FREE BASE OF 2-HYDROXY-6 - ((2- (1-ISOPROPYL-1H-PYRAZOL-5-YL) PYRIDIN-3-YL) METHOXY) BENZALDEHYDE
|
WO2015184305A1
(en)
|
2014-05-30 |
2015-12-03 |
Incyte Corporation |
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
|
MA41841A
(en)
|
2015-03-30 |
2018-02-06 |
Global Blood Therapeutics Inc |
ALDEHYDE COMPOUNDS FOR THE TREATMENT OF PULMONARY FIBROSIS, HYPOXIA, AND AUTOIMMUNE AND CONNECTIVE TISSUE DISEASES
|
MA43373A
(en)
|
2015-12-04 |
2018-10-10 |
Global Blood Therapeutics Inc |
DOSAGE REGIMES FOR 2-HYDROXY-6 - ((2- (1-ISOPROPYL-1H-PYRAZOL-5-YL) PYRIDIN-3-YL) METHOXY) BENZALDEHYDE
|
AR108435A1
(en)
|
2016-05-12 |
2018-08-22 |
Global Blood Therapeutics Inc |
PROCESS TO SYNTHETIZE 2-HYDROXI-6 - ((2- (1-ISOPROPIL-1H-PIRAZOL-5-IL) -PIRIDIN-3-IL) METOXI) BENZALDEHYDE
|
CN107513067A
(en)
|
2016-06-16 |
2017-12-26 |
北京赛林泰医药技术有限公司 |
Pyrrolopyrimidine compounds containing substituted cyclopenta
|
US10154992B2
(en)
*
|
2016-07-12 |
2018-12-18 |
The Regents Of The University Of California |
Compounds and methods for treating HIV infection
|
JOP20190024A1
(en)
|
2016-08-26 |
2019-02-19 |
Gilead Sciences Inc |
Substituted pyrrolizine compounds and uses thereof
|
TWI778983B
(en)
|
2016-10-12 |
2022-10-01 |
美商全球血液治療公司 |
Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
|
US10596161B2
(en)
|
2017-12-08 |
2020-03-24 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
WO2019152374A1
(en)
|
2018-01-30 |
2019-08-08 |
Incyte Corporation |
Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
|
EP3759109B1
(en)
|
2018-02-26 |
2023-08-30 |
Gilead Sciences, Inc. |
Substituted pyrrolizine compounds as hbv replication inhibitors
|
MX2022012285A
(en)
|
2018-03-30 |
2023-08-15 |
Incyte Corp |
Treatment of hidradenitis suppurativa using jak inhibitors.
|
WO2020072377A1
(en)
|
2018-10-01 |
2020-04-09 |
Global Blood Therapeutics, Inc. |
Modulators of hemoglobin for the treatment of sickle cell disease
|
TW202039481A
(en)
|
2018-12-21 |
2020-11-01 |
美商西建公司 |
Thienopyridine inhibitors of ripk2
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|